AOD-9604 vs Tirzepatide
Compare AOD-9604, Tirzepatide: half-life, time to Cmax, dosing interval, published dose ranges and titration — citation-backed, research use only.
| AOD-9604View AOD-9604 → | TirzepatideMounjaro, ZepboundView Tirzepatide → | |
|---|---|---|
| Class | Metabolic | GLP-1 |
| Route | Subcutaneous | Subcutaneous |
| Plasma half-life | 1 h | ~5.0 days (120 h) |
| Time to Cmax | ~30 min | 36 h |
| Typical interval | Once daily | Once weekly |
| Published dose range | 0.3–0.5 mg | 2.5–15 mg |
| Titration ladder | No preset ladder | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg |
| Summary | Hexadecapeptide fragment (177-191) of human growth hormone. Studied for lipolytic effects. | Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path. |
Source references
AOD-9604
- Heffernan M et al., Endocrinology 142:5182 (2001)
Tirzepatide
- FDA Mounjaro USPI — half-life ~5 days (120 h) (2024)
- SURPASS-2 trial — NEJM 385:503 (2021)
- Urva S et al., Clin Pharmacokinet 61:1057 (Tmax 24–72 h) (2022)
For research use only. Not for human consumption. This tracker visualises only the doses you have logged or scheduled — it does not recommend dose sizes, does not suggest what to take, and is not pharmacokinetically calibrated. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. Consult a licensed clinician before making any medical decision.